HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34292325/
1 Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA. 2 Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. 3 Division...
Graft Versus Host Disease After Intestinal Transplantation: A Single-center Experience - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34291153/
doi: 10.1097/TXD.0000000000001187. 1 MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC. 2 Georgetown University School of Medicine, Washington, DC. 3 Histocompatibility Laboratory, MedStar Georgetown University Hospital, Washington, DC....
Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34276662/
doi: 10.3389/fimmu.2021.673636. 1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow...
Hypoxemic respiratory failure following ruxolitinib discontinuation in allogeneic hematopoietic cell transplantation recipients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34272781/
Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly being used in allogeneic hematopoietic cell transplantation (HCT) recipients, following its approval by the US Food and Drug...
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34260836/
Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was greater with ruxolitinib....
-
Naveed Saleh, MD, MS – Skipta Team4yrKey Points • Conclusion/Relevance: “Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was Show More